# of Displayed Technologies: 13 / 13

Applied Category Filter (Click To Remove): Peptides/Proteins


Categories

Cell-Penetrating Peptides: Revolutionizing Intracellular Delivery
TS-066751 — In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Traditional methods face challenges with membrane impermeability and degradation of therapeutic compounds, limiting th…
  • College: College of Arts & Sciences
  • Inventors: Pei, Dehua
  • Licensing Officer: Dahlman, Jason "Jay"

Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
  • College: College of Medicine (COM)
  • Inventors: Kerur, Nagaraj
  • Licensing Officer: Willson, Christopher

Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: OSU Wexner Medical Center
  • Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
  • Licensing Officer: Willson, Christopher

A Breakthrough in Central Nervous System Repair
TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.
In the realm of central nervous system (CNS) repair, a critical need arises for innovative treatments that not only address the physical aspects of injury but also tackle the associated phychopathology. Understanding the cellular processes that occur after spinal cord injury (SCI) that are detrimen…
  • College: College of Medicine (COM)
  • Inventors: Tedeschi, Andrea
  • Licensing Officer: Willson, Christopher

Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Medicine (COM)
  • Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
  • Licensing Officer: Taysavang, Panya

Purification of apoproteins and general methods for protein purification
TS-062540 — General methods for purifying proteins that can be used in various applications such as targeted drug delivery, bioimaging, and hemolysis treatment.
The Need Novel protein and apoprotein purification strategies are valuable tools with a wide variety of medical and research applications. While there are existing techniques for protein and apoprotein purification, some of these have flaws such as the use of harsh denaturants, highly flammable sol…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Schworer, Adam

Peptide-based therapeutic intervention for Cardiac Ryanopathies
TS-062097 — Novel polypeptides and polynucleotides targeting RyR2 to address dysregulated Ca2+ release.
The cardiac ryanodine receptor channel 2 (RyR2) is known as the Ca2+ release channel of the sarcoplasmic reticulum (SR), and is believed to be a good therapeutic target in a group of certain heart diseases, known as cardiac ryanopathies. A number of mutations in the RyR2 gene have been linked to a w…
  • College: College of Medicine (COM)
  • Inventors: Singh, Harpreet
  • Licensing Officer: Willson, Christopher

Therapeutic uses of the scavenging protein cocktail to treat plasma protein imbalances or depletion
TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.
Fluid replacement as part of resuscitation efforts in clinical care is a cornerstone of treatment especially in cases with severe trauma. The regular usage of these fluids in hospitals requires the mixture to be easily transported, easily stored and applicable across a wide variety of patients. To…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Palmer, Andre
  • Licensing Officer: Schworer, Adam

Novel acellular vaccine for protection against Bordetella infection
TS-050524 — Despite high vaccine coverage, whooping cough caused by Bordetella pertussis remains one of the most common vaccine-preventable diseases worldwide. Introduction of whole-cell pertussis (wP) vaccines in the 1940s and acellular pertussis (aP) vaccines in 1990s reduced mortality due to pertussis. Des…
  • College: College of Medicine (COM)
  • Inventors: Deora, Rajendar; Mishra, Meenu; Sukumar, Neelima
  • Licensing Officer: He, Panqing

Mini-PCDH15 for treatment of deafness
TS-050433 — A gene therapy solution for Usher Syndrome Type 1F.
Mutations in PCDH15 cause Usher 1F, a recessive syndrome characterized by profound congenital deafness and absence of vestibular function, and progressive blindness beginning in the second decade. Because patients who lack hearing and balance rely on vision for communication and mobility, the late…
  • College: College of Arts & Sciences
  • Inventors: Sotomayor, Marcos
  • Licensing Officer: Dahlman, Jason "Jay"

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Cripe, Timothy; Kudryashova, Elena; Purde, Vedud
  • Licensing Officer: Panic, Ana

Immunomodulating agents engineered from Notch receptor ligand extracellular domains
TS-036760 — Immunomodulating agents have been engineered from Notch receptor ligand extracelluar domains. These are useful for stimulating the immune system.
The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Carbone, David; Dikov, Mikhail; Long, Nicholas; Sullivan, Brandon; Tchekneva, Elena
  • Licensing Officer: Dahlman, Jason "Jay"

Self-Assembly of Therapeutic-Agent Nanostructures
TS-014812 — An improved delivery mechanism has been developed for hydrophobic drugs such as camptothecin which will increase chemotherapeutic efficacy.
Many cancer therapeutics exhibit extremely toxic side effects or have limited efficacy due to low bio-availability. Existing drug delivery technologies can add excessive mass to the therapeutic, grossly expanding the dosage necessary for response. Camptothecin (CPT) is a naturally occurring compou…
  • College: College of Arts & Sciences
  • Inventors: Parquette, Jonathan; Grinstaff, Mark; Kaplan, Jonah; Kim, Se Hye
  • Licensing Officer: Dahlman, Jason "Jay"

Loading icon